SSXT (also known as SS18) appears to function synergistically with RBM14 as a transcriptional coactivator [].The SSXT protein is involved in synovial sarcoma in humans. A SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18) (p11;q11) is characteristic of synovial sarcomas. This translocation fuses the SSXT (SYT) gene from chromosome 18 to either of two homologous genes at Xp11, SSX1 or SSX2 [].The SS18 family also includes SS18-like proteins 1 and 2, and GRF1-interacting factors from plants []. SS18-like protein 1 is a transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons [, ].
This entry represents the N-terminal domain of SS18 and related proteins.SSXT (also known as SS18) appears to function synergistically with RBM14 as a transcriptional coactivator [].The SSXT protein is involved in synovial sarcoma in humans. A SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18) (p11;q11) is characteristic of synovial sarcomas. This translocation fuses the SSXT (SYT) gene from chromosome 18 to either of two homologous genes at Xp11, SSX1 or SSX2 [].The SS18 family also includes SS18-like proteins 1 and 2, and GRF1-interacting factors from plants []. SS18-like protein 1 is a transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons [, ].
This entry represents the SSX family, including SSX1-9. They are identified as cancer testis antigens and can act as a transcription modulator. Some members of this family can become fused to the SS18 protein in synovial sarcoma (SS) through gene translocations []. In humans, SSX1-9 have a N-terminal KRAB (Krüppel-associated box) domain and a C-terminal RD (repression domain). The RD domain mediates repression of transcription and can be translocated to the C-terminal end of SYT in synovial sarcoma [].
